Target intelligence / Profile preview

Sodium-glucose cotransporter 1 (SGLT1)

Target
SGLT1
Molecular classification
Transporter, Membrane protein, Solute carrier family (SLC5A1)
01

Overview

"Glucose absorption in intestine" is not itself a molecular target but describes a physiological process primarily mediated by specific transporters. The key molecular target responsible for intestinal glucose absorption is Sodium-glucose cotransporter 1 (SGLT1). This transporter is located on the apical membrane of enterocytes lining the small intestine and mediates active uptake of dietary glucose from the lumen into cells using energy from sodium gradients[4][6]. After entry via SGLT1, glucose exits into circulation through basolateral facilitative transporters such as GLUT2[2][3]. SGLT1 also plays an essential role in glucose-induced incretin hormone secretion—notably GIP and GLP‑1—which are important for insulin release after meals[2]. Loss or inhibition of SGLT1 drastically reduces both intestinal glucose uptake and incretin responses[2][3]. While GLUT2 has been proposed to contribute to bulk facilitated diffusion under high luminal concentrations, evidence indicates that SGLT1 remains indispensable even at high loads, with GLUT2's main role being basolateral exit rather than apical entry under most physiological conditions[3][5]. The query refers to "Glucose absorption in intestine" as if it were a single molecule or receptor. In reality, this term describes a process involving multiple proteins—primarily Sodium-glucose cotransporter 1 (SGLT1) but also including others like GLUT2. For structured data purposes, it should be mapped specifically to "Sodium-glucose cotransporter 1," not left as an unstructured process name[4][6].

Other names
Sodium-glucose linked transporter 1SLC5A1sodium-dependent glucose cotransporter 1
02

Mechanism of action

Inhibitors block active sodium-coupled glucose uptake at the apical membrane, reducing postprandial blood glucose rise.

03

Biological functions

Glucose absorption in the small intestineGlucose sensing and regulation of incretin hormone secretion (GIP and GLP-1)Active transport of glucose across the apical membrane of enterocytes
04

Disease associations

Diabetes mellitusObesityMalabsorption syndromes
05

Safety considerations

Inhibition can cause gastrointestinal side effects such as diarrhea and malabsorption.
06

Interacting drugs

Phlorizin (experimental inhibitor)
07

Biomarkers

Expression levels of SGLT1 in intestinal tissue may serve as a biomarker for absorption capacity or therapeutic response.

Beyond the preview

Go deeper on Sodium-glucose cotransporter 1 (SGLT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-glucose cotransporter 1 (SGLT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call